2012
The drive to eat: comparisons and distinctions between mechanisms of food reward and drug addiction
DiLeone RJ, Taylor JR, Picciotto MR. The drive to eat: comparisons and distinctions between mechanisms of food reward and drug addiction. Nature Neuroscience 2012, 15: 1330-1335. PMID: 23007187, PMCID: PMC3570269, DOI: 10.1038/nn.3202.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2010
Galanin and Addiction
Picciotto MR. Galanin and Addiction. EXS 2010, 102: 195-208. PMID: 21299070, DOI: 10.1007/978-3-0346-0228-0_14.Peer-Reviewed Original ResearchConceptsGalanin receptorsFood intakeOpiate rewardDrug rewardAbility of neuropeptidesMesolimbic dopamine systemDrugs of abuseGalanin agonistsNoradrenergic neuronsDrug withdrawalStriatal slicesWithdrawal signsAnalgesic propertiesLocus coeruleusHypothalamic functionDopamine releaseGalaninDopamine systemNovel treatmentsPlace preferenceStress-related pathwaysFiring ratePotential targetWithdrawalIntake
2009
Effects of galanin on monoaminergic systems and HPA axis: Potential mechanisms underlying the effects of galanin on addiction- and stress-related behaviors
Picciotto MR, Brabant C, Einstein EB, Kamens HM, Neugebauer NM. Effects of galanin on monoaminergic systems and HPA axis: Potential mechanisms underlying the effects of galanin on addiction- and stress-related behaviors. Brain Research 2009, 1314: 206-218. PMID: 19699187, PMCID: PMC2819596, DOI: 10.1016/j.brainres.2009.08.033.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBiogenic MonoaminesBrainGalaninHumansHypothalamo-Hypophyseal SystemLimbic SystemReceptors, GalaninStress, PsychologicalSubstance Withdrawal SyndromeSubstance-Related DisordersConceptsEffects of galaninStress-related behaviorsDrugs of abuseGalanin receptorsAbility of galaninPotential mechanismsAddiction-related disordersDrug-related behaviorsNumber of neuropeptidesGalanin effectsHPA axisMonoaminergic systemsDrug exposureTreatment of stressNeuronal activityGalaninBrain areasNeuronal functionBrain regionsAddictive drugsBrain circuitsNovel therapeuticsDrugsNeural activityReceptors
2008
Galanin – 25 years with a multitalented neuropeptide
Picciotto MR. Galanin – 25 years with a multitalented neuropeptide. Cellular And Molecular Life Sciences 2008, 65: 1872-1879. PMID: 18500649, PMCID: PMC11131873, DOI: 10.1007/s00018-008-8151-x.Peer-Reviewed Original ResearchMeSH KeywordsAcetylcholineAlcohol DrinkingAnimalsDopamineGalaninHumansLocomotionMiceMorphineRewardSignal TransductionSubstance Withdrawal SyndromeSubstance-Related DisordersConceptsGalanin receptorsFood intakeOpiate rewardDrug rewardGalanin – 25 yearsAbility of neuropeptidesMesolimbic dopamine systemDrugs of abuseGalanin agonistsNoradrenergic neuronsDrug withdrawalStriatal slicesWithdrawal signsAnalgesic propertiesLocus coeruleusHypothalamic functionDopamine releaseDopamine systemGalaninNovel treatmentsPlace preferenceStress-related pathwaysFiring ratePotential targetWithdrawal
2006
Galanin: a novel therapeutic target for depression, anxiety disorders and drug addiction?
Holmes A, Picciotto MR. Galanin: a novel therapeutic target for depression, anxiety disorders and drug addiction? CNS & Neurological Disorders - Drug Targets 2006, 5: 225-32. PMID: 16611095, DOI: 10.2174/187152706776359600.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAnxiety DisordersBiogenic AminesBrainDepressive DisorderGalaninHumansStress, PsychologicalSubstance Withdrawal SyndromeSubstance-Related DisordersConceptsStress-related neural pathwaysBrain stress pathwaysSerotonin-producing neuronsDistribution of galaninDepression-related behaviorsDorsal raphe nucleusExpression of galaninAdministration of galaninNovel therapeutic targetDrug addictionPotential roleAnxiety-like responsesGalanin agonistsGalanin systemRaphe nucleusDopamine neuronsOpiate withdrawalLocus coeruleusNeuronal typesRodent modelsCurrent evidenceGalaninPsychiatric disordersTherapeutic targetOpiate reinforcement
2002
Acute and long‐term changes in the mesolimbic dopamine pathway after systemic or local single nicotine injections
Ferrari R, Le Novère N, Picciotto MR, Changeux JP, Zoli M. Acute and long‐term changes in the mesolimbic dopamine pathway after systemic or local single nicotine injections. European Journal Of Neuroscience 2002, 15: 1810-1818. PMID: 12081661, DOI: 10.1046/j.1460-9568.2001.02009.x.Peer-Reviewed Original ResearchMeSH KeywordsAmphetamineAnimalsDopamineDopamine Plasma Membrane Transport ProteinsDrug Administration RoutesExtracellular SpaceHabituation, PsychophysiologicMaleMembrane GlycoproteinsMembrane Transport ProteinsMicrodialysisMotor ActivityNerve Tissue ProteinsNeural PathwaysNeuronal PlasticityNicotineNucleus AccumbensPresynaptic TerminalsRatsRats, Sprague-DawleyReceptors, AMPAReceptors, N-Methyl-D-AspartateRNA, MessengerSubstance-Related DisordersTime FactorsTyrosine 3-MonooxygenaseVentral Tegmental AreaConceptsDialysate DA levelsGluR1 mRNA levelsSingle nicotine injectionNicotine administrationDA levelsMesolimbic dopamine pathwayNicotine injectionTyrosine hydroxylaseDopamine pathwayMRNA levelsBasal DA levelsExtracellular DA levelsMesolimbic DA pathwaySystemic intraperitoneal injectionTH mRNA levelsIntra-accumbens infusion
1998
Common aspects of the action of nicotine and other drugs of abuse
Picciotto M. Common aspects of the action of nicotine and other drugs of abuse. Drug And Alcohol Dependence 1998, 51: 165-172. PMID: 9716938, DOI: 10.1016/s0376-8716(98)00074-x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAnimalsAnti-Anxiety AgentsBehavior, AddictiveCentral Nervous System StimulantsCognitionHumansIllicit DrugsMotor ActivityNicotineNicotinic AgonistsNucleus AccumbensReceptors, NicotinicRewardSelf MedicationSubstance Withdrawal SyndromeSubstance-Related DisordersTobacco Use DisorderVentral Tegmental Area